These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32012878)

  • 1. Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma.
    Sun J; Muz B; Alhallak K; Markovic M; Gurley S; Wang Z; Guenthner N; Wasden K; Fiala M; King J; Kohnen D; Salama NN; Vij R; Azab AK
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.
    Zhuang Z; Zhou J; Qiu M; Li J; Lin Z; Yi H; Liu X; Huang C; Tang B; Liu B; Li X
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
    Zhang C; Liu Y; Jiang J; Chen C; Duan Z; Su H; Wang S; Tian B; Shi Y; Xiang R; Luo Y
    Theranostics; 2024; 14(7):2757-2776. PubMed ID: 38773982
    [No Abstract]   [Full Text] [Related]  

  • 5. The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma.
    Schürch CM; Forster S; Brühl F; Yang SH; Felley-Bosco E; Hewer E
    Oncoimmunology; 2017; 7(1):e1373235. PubMed ID: 29296529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Anti-CD47 Peptides as Innate Immune Checkpoint Inhibitors.
    Mustafa B; Fetse J; Kandel S; Lin CY; Adhikary P; Mamani UF; Liu Y; Ibrahim MN; Alahmari M; Cheng K
    Adv Ther (Weinh); 2023 Dec; 6(12):. PubMed ID: 38655206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.
    Tian L; Xu B; Teng KY; Song M; Zhu Z; Chen Y; Wang J; Zhang J; Feng M; Kaur B; Rodriguez L; Caligiuri MA; Yu J
    Clin Cancer Res; 2022 Jan; 28(1):201-214. PubMed ID: 34645647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies.
    Sun J; Chen Y; Lubben B; Adebayo O; Muz B; Azab AK
    Leuk Res Rep; 2021; 16():100268. PubMed ID: 34584838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Don't eat me/eat me signals as a novel strategy in cancer immunotherapy.
    Khalaji A; Yancheshmeh FB; Farham F; Khorram A; Sheshbolouki S; Zokaei M; Vatankhah F; Soleymani-Goloujeh M
    Heliyon; 2023 Oct; 9(10):e20507. PubMed ID: 37822610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
    Tong B; Wang M
    Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma.
    Tang XX; Shimada H; Ikegaki N
    Curr Oncol; 2024 Jun; 31(6):3212-3226. PubMed ID: 38920727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
    Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.
    Kim D; Wang J; Willingham SB; Martin R; Wernig G; Weissman IL
    Leukemia; 2012 Dec; 26(12):2538-45. PubMed ID: 22648449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal.
    Li C; Liu Y; Li D; Wang Q; Zhou S; Zhang H; Wang Y; He Z; Liu H; Sun J
    Theranostics; 2022; 12(10):4581-4598. PubMed ID: 35832081
    [No Abstract]   [Full Text] [Related]  

  • 16. Nanoparticle-Enabled Dual Modulation of Phagocytic Signals to Improve Macrophage-Mediated Cancer Immunotherapy.
    Zhang YR; Luo JQ; Zhang JY; Miao WM; Wu JS; Huang H; Tong QS; Shen S; Leong KW; Du JZ; Wang J
    Small; 2020 Nov; 16(46):e2004240. PubMed ID: 33107142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.
    van Bommel PE; He Y; Schepel I; Hendriks MAJM; Wiersma VR; van Ginkel RJ; van Meerten T; Ammatuna E; Huls G; Samplonius DF; Helfrich W; Bremer E
    Oncoimmunology; 2018; 7(2):e1386361. PubMed ID: 29308308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation.
    Li Z; Gu X; Rao D; Lu M; Wen J; Chen X; Wang H; Cui X; Tang W; Xu S; Wang P; Yu L; Ge X
    Transl Oncol; 2021 Aug; 14(8):101129. PubMed ID: 34051623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.
    Swoboda DM; Sallman DA
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101221. PubMed ID: 33279177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors.
    Tzatzarakis E; Hissa B; Reissfelder C; Schölch S
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):993-999. PubMed ID: 31686549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.